The following companies are expected to report earnings prior to market open on 03/12/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Aclaris Therapeutics, Inc. ( ACRS ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.90. This value represents a 83.67% decrease compared to the same quarter last year. In the past year ACRS has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 26.74%. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ACRS is -7.94 vs. an industry ratio of -7.90.
ViewRay, Inc. ( VRAY ) is reporting for the quarter ending December 31, 2017. The medical instruments company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.25. This value represents a no change for the same quarter last year. The "days to cover" for this stock exceeds 16 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for VRAY is -7.60 vs. an industry ratio of 18.30.
Tsakos Energy Navigation Ltd ( TNP ) is reporting for the quarter ending December 31, 2017. The shipping company's consensus earnings per share forecast from the 6 analysts that follow the stock is $-0.04. This value represents a 140.00% decrease compared to the same quarter last year. The last two quarters TNP had negative earnings surprises; the latest report they missed by -20%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TNP is -84.25 vs. an industry ratio of 20.90.
Minerva Neurosciences, Inc ( NERV ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.43. This value represents a 59.26% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for NERV is -4.34 vs. an industry ratio of -7.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Egalet Corporation ( EGLT ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.38. This value represents a 56.32% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 17 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for EGLT is -0.26 vs. an industry ratio of -7.90, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.